Steroidal 5α-reductase inhibitors using 4-androstenedione as substrate

References

• Lee HJ, Chang C. Recent advances in androgen receptor action. Cell Mol Life Sci 2003;60:1613–1622.
   PubMed Web of Science ®Google Scholar
• Weisser H, Krieg M. Kinetic analysis of androstenedione 5α-reductase in epithelium and stroma of human prostate. Steroids 1997;62:589–594.
   PubMedGoogle Scholar
• Bélanger B, Bélanger A, Labrie F, Dupont A, Cusan L, Monfette G. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem 1989;32:695–698.
   PubMedGoogle Scholar
• Luu-The V, Bélanger A, Labrie F. Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 2008;22:207–221.
   PubMed Web of Science ®Google Scholar
• Russell DW, Wilson JD. Steroid 5α-reductase: two genes/two enzymes. Annu Rev Biochem 1994;63:25–61.
   PubMed Web of Science ®Google Scholar
• Liang T, Cascieri MA, Cheung AH, Reynolds GF, Rasmusson GH. Species differences in prostatic steroid 5α-reductases of rat, dog, and human. Endocrinology 1985;117:571–579.
   PubMed Web of Science ®Google Scholar
• Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O’Brien SP et al. Differential alterations in 5α-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005;63:231–239.
   PubMed Web of Science ®Google Scholar
• Bonkhoff H, Stein U, Aumüller G, Remberger K. Differential expression of 5α-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 1996;29:261–267.
   PubMed Web of Science ®Google Scholar
• Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y et al. Novel 5α-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008;99:81–86.
   PubMed Web of Science ®Google Scholar
• Samson M, Labrie F, Zouboulis CC, Luu-The V. Biosynthesis of dihydrotestosterone by a pathway that does not require testosterone as an intermediate in the SZ95 sebaceous gland cell line. J Invest Dermatol 2010;130:602–604.
   PubMed Web of Science ®Google Scholar
• Bratoeff E, García P, Heuze Y, Soriano J, Mejía A, Labastida AM et al. Molecular interactions of progesterone derivatives with 5α-reductase types 1 and 2 and androgen receptors. Steroids 2010;75:499–505.
   PubMed Web of Science ®Google Scholar
• Hirosumi J, Nakayama O, Fagan T, Sawada K, Chida N, Inami M et al. FK143, a novel nonsteroidal inhibitor of steroid 5α-reductase: (1) In vitro effects on human and animal prostatic enzymes. J Steroid Biochem Mol Biol 1995;52:357–363.
   PubMed Web of Science ®Google Scholar
• Bratoeff E, Sainz T, Cabeza M, Heuze I, Recillas S, Pérez V et al. Steroids with a carbamate function at C-17, a novel class of inhibitors for human and hamster steroid 5α-reductase. J Steroid Biochem Mol Biol 2007;107:48–56.
   PubMedGoogle Scholar
• Bradford MM. A rapid and sensitive method for the quantization of micrograms quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1986;72:248–254.
   Web of Science ®Google Scholar
• Lineweaver H, Burk D. The determination of enzyme dissociation constants. J Am Chem 1934;54:658–666.
   Google Scholar
• Segel IH. Enzyme kinetics. Behavior and analysis of rapid equilibrium and steady state enzyme systems. New York: John Wiley & Sons, INC. New York, 1993:37–51.
   Google Scholar
• Pelletier G. Expression of steroidogenic enzymes and sex-steroid receptors in human prostate. Best Pract Res Clin Endocrinol Metab 2008;22:223–228.
   PubMed Web of Science ®Google Scholar
• Dufort I, Rheault P, Huang XF, Soucy P, Luu-The V. Characteristics of a highly labile human type 5 17β-hydroxysteroid dehydrogenase. Endocrinology 1999;140:568–574.
   PubMed Web of Science ®Google Scholar
• Krieg M, Weisser H, Tunn S. Potential activities of androgen metabolizing enzymes in human prostate. J Steroid Biochem Mol Biol 1995;53:395–400.
   PubMed Web of Science ®Google Scholar
• Raynaud JP. Prostate cancer risk in testosterone-treated men. J Steroid Biochem Mol Biol 2006;102:261–266.
   PubMed Web of Science ®Google Scholar
• Wright AS, Douglas RC, Thomas LN, Lazier CB, Rittmaster RS. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5α-reductase. Endocrinology 1999;140:4509–4515.
   PubMed Web of Science ®Google Scholar
• Dadras SS, Cai X, Abasolo I, Wang Z. Inhibition of 5α-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone. Gene Expr 2001;9:183–194.
   PubMed Web of Science ®Google Scholar
• Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proc Natl Acad Sci USA 1990;87:3640–3644.
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, López-Solache I, Labrie F, Luu-The V. Cations inhibit specifically type I 5α-reductase found in human skin. J Invest Dermatol 1995;104:775–778.
   PubMed Web of Science ®Google Scholar
• Hudson RW, Wherrett D. Comparison of the nuclear 5α-reduction of testosterone and androstenedione in human prostatic carcinoma and benign prostatic hyperplasia. J Steroid Biochem 1990;35:231–236.
   PubMedGoogle Scholar
• Weisser H, Tunn S, Debus M, Krieg M. 5α-reductase inhibition by finasteride (Proscar) in epithelium and stroma of human benign prostatic hyperplasia. Steroids 1994;59:616–620.
   PubMedGoogle Scholar
• Weisser H, Krieg M. In vitro inhibition of androstenedione 5α-reduction by finasteride in epithelium and stroma of human benign prostatic hyperplasia. J Steroid Biochem Mol Biol 1998;67:49–55.
   PubMed Web of Science ®Google Scholar